Brent Zettl, the former CEO of Canadian licensed producer CanniMed Therapeutics, is back in action with a brand new cannabis-related business, only this time they won’t be growing the stuff.
Given that CanniMed was acquired by Aurora Cannabis Inc. (TSX:ACB) (NYSE:ACB) for over $1 billion CAD, many investors, whether they made money or missed out, are sure to be interested in Zettl’s next deal.
ZYUS Life Sciences Inc.
ZYUS Life Sciences Inc., previously called CB3 Life Sciences Inc., is a biopharmaceutical company focusing on international production and distribution of “phyto-therapeutic compounds”, leading with cannabis-based medicines. Along with his former team, Zettl intends to “forge a new industry of phyto-therapeutics and elevate its solutions as a standard of care for treating disease and managing the experience of it.”
Brent Zettl, President and CEO of ZYUS Life Sciences commented:
“Pronounced “ZEYE-us”, our name is an abstraction of the word ‘science’ + ‘zygote’ (the fusion of two cells), representing the beginning of life and symbolizing our aim to improve quality of life. It also embeds ‘us’ as a reference to our teamwork, partnerships and our commitment to the broader ‘us’ – society. The name conveys our forward-looking and collaborative approach to bringing phyto-therapeutics to market.”
ZYUS Life Sciences’ Business Plan
According to the announcement:
“ZYUS’ fundamental business plan in cannabis is to be a global-scale producer of value-added medical-grade cannabis oil and oil-derived products such as capsules and topical cream.
ZYUS is upgrading a global-scale ethanol extraction facility which will source dry herbal feedstock cannabis material from multiple Canadian licensed cannabis producers (LPs), thereby taking advantage of a dry herbal capacity overbuild widely anticipated to emerge within the next one to two years. ZYUS is solely focused on the development of pharmaceutical-grade medicinal oil products and dedicated to improving patient well-being, which is highly unique and well placed relative to the overall direction of the domestic and global industry.
The timing for ZYUS’ business plan is particularly attractive due to a number of industry trends and indicators. Cannabis oil and oil derivative products are poised to become the majority of the domestic and global cannabis markets. These markets are anticipated to grow rapidly over the next ten years. These value-added oil products require a high level of expertise to successfully establish commercial extraction facilities and produce pharmaceutical-grade cannabinoid formulations on scale.”
ZYUS Life Sciences’ Facility Details
According to the announcement:
“The ZYUS extraction facility in Saskatoon, Saskatchewan will be constructed in two phases. Phase 1, currently being designed and constructed and targeted for completion early 2019, will be capable of producing the equivalent of approximately 500,000, 50ml bottles of cannabis oil per annum. Even in this pilot phase, the ZYUS facility will have significant capacity.
The ZYUS global-scale, world-class, extraction facility, targeted to be fully commissioned in the first half of 2020, is anticipated to be one of the largest cannabis extraction facilities in the world, with annual total projected processing capacity of 350,000kg of dry herbal cannabis, or 35 million 50ml bottles equivalent of cannabis oil per annum.”
Having raised $25 million CAD from accredited investors across Canada, the United States, the United Kingdom, and Germany, ZYUS Life Sciences is certainly well capitalized. With no existing infrastructure other than an impressive management team, ZYUS is currently a bet on the jockeys. In the interim, be sure to subscribe to updates here so you never miss an important update.
Get Real-Time Updates from The Daily Marijuana Observer